MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT ‐737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment

British Journal of Haematology, EarlyView.

Source: British Journal of Haematology - May 16, 2018 Category: Hematology Authors: Kyle Crassini , Yandong Shen , William S. Stevenson , Richard Christopherson , Chris Ward , Stephen P. Mulligan , O. Giles Best Source Type: research